This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.


The original disclosure in Japanese was released on December 15, 2016

Takara Holdings Inc.


Notice Regarding Change in Sub-Subsidiary

Takara Bio Inc., a consolidated subsidiary of Takara Holdings, resolved at a Board of Directors’ meeting held on December 15, 2016 to sign a merger agreement pursuant to which Takara Bio USA Holdings Inc., a wholly-owned subsidiary of Takara Bio, will acquire Rubicon Genomics, Inc., and executed the agreement. By this agreement, Rubicon Genomics, Inc. will become a specified subsidiary of the Company. For details, please refer to the news release entitled "Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement” released today by Takara Bio.


The impact of the change on consolidated earnings for the fiscal year ending March 31, 2017, currently being assessed along with other factors, is expected to be immaterial. Should it be judged necessary for performance forecasts to be revised, notice will be given in a timely manner.